ライフサイエンスコーパス: clinical laboratory

1 lack of active surveillance tests hamper the clinical laboratory.

2 tional HIV- BDD were measured in 20 BDD in a clinical laboratory.

3 he use of bacteriophage amplification in the clinical laboratory.

4 pin, and mupirocin) performed by the routine clinical laboratory.

5 on time and materials not often found in the clinical laboratory.

6 rofiles obtained with routine methods in the clinical laboratory.

7 ults of exome sequencing of 1,248 cases in a clinical laboratory.

8 is where this testing should be done in the clinical laboratory.

9 ations for implementation of the method in a clinical laboratory.

10 0.50/sample) for yeast identification in the clinical laboratory.

11 s that could aid in their recognition in the clinical laboratory.

12 n (308) and infrequent (132) isolates in the clinical laboratory.

13 to read and is readily incorporate into the clinical laboratory.

14 se activity are periodically isolated by the clinical laboratory.

15 pplication in biomedical research and in the clinical laboratory.

16 the total bilirubin values determined in the clinical laboratory.

17 for rapid point-of-care testing of miRNAs in clinical laboratory.

18 or reliable measurement of viral load in the clinical laboratory.

19 icrobiota profiling scheme may be adopted by clinical laboratories.

20 r of Enterobacteriaceae commonly isolated by clinical laboratories.

21 producing organisms is a major challenge for clinical laboratories.

22 an accuracy base for routine methods used in clinical laboratories.

23 l ensure that they will both have a niche in clinical laboratories.

24 come a common technique in both research and clinical laboratories.

25 at NGS technology is ready to be deployed in clinical laboratories.

26 ent of diagnostic proteins, such as HbA2, in clinical laboratories.

27 ty hospitals, physicians' offices, and small clinical laboratories.

28 abundance proteins is gaining popularity in clinical laboratories.

29 s, including small research laboratories and clinical laboratories.

30 e quantification of proteins is essential in clinical laboratories.

31 should be broadly applicable to research and clinical laboratories.

32 ification systems that are currently used in clinical laboratories.

33 itate prompt diagnosis of STEC infections in clinical laboratories.

34 atly simplify rifampin resistance testing in clinical laboratories.

35 been widely adopted in the United States by clinical laboratories.

36 our assay to be useful in both research and clinical laboratories.

37 s-three genes that are commonly sequenced in clinical laboratories.

38 eriaceae will likely lead to its adoption by clinical laboratories.

39 California Department of Public Health or at clinical laboratories.

40 ymptomatic donors present many challenges to clinical laboratories.

41 can ideally be performed at resource-limited clinical laboratories.

42 n misidentified by methods used routinely in clinical laboratories.

43 ibility testing methods that are feasible in clinical laboratories.

44 on and limit of quantification chosen by the clinical laboratory, (3) the linear range of the assay,

45 This paradigm is changing as clinical laboratories adopt culture-independent methods,

46 The 2009 H1N1 ID kit offers clinical laboratories an alternative to RT-PCR for the i

47 Although morphology and clinical laboratory analysis continue to play an importa

48 rnative nucleic acid amplification assay for clinical laboratories and clinicians.

49 Frederick Nolte is the Director of Clinical Laboratories and Director of Molecular Patholog

50 everse algorithm may not be suitable for all clinical laboratories and every clinical situation.

51 tandard approach but is impractical for many clinical laboratories and is often replaced with PCR-bas

52 (PCR) is widely used as a diagnostic tool in clinical laboratories and is particularly effective for

53 discordance of variant classification among clinical laboratories and prevents definitive classifica

54 duce the burden of the proposed new rules on clinical laboratories and protect patients' access to st

55 new breakpoints for these agents for use in clinical laboratories and provided updated recommendatio

56 e specimens were tested at the participating clinical laboratories and were all accurately detected b

57 Safety evaluation was based on clinical laboratory and adverse events (AEs) reports.

58 ria LAMP assay was easily implemented in the clinical laboratory and gave similar results to a real-t

59 or infectious diseases currently used in the clinical laboratory and in point-of-care devices are div

60 T were conducted in eight laboratories using Clinical Laboratory and Standards Institute (CLSI) guide

61 ed in eight participating laboratories using Clinical Laboratory and Standards Institute (CLSI) guide

62 Using Clinical Laboratory and Standards Institute (CLSI)-recom

63 are the only antifungal agents for which the Clinical Laboratory and Standards Institute recommendati

64 We propose to the Clinical Laboratory and Standards Institute that isolate

65 tification of Gram-negative organisms in the clinical laboratory and that meaningful performance impr

66 l hands-on time that can be implemented in a clinical laboratory and used directly on clinical specim

67 reported BSL-3 laboratory support via their clinical laboratory and/or PHL.

68 Poisson regression identified clinical, laboratory and demographic predictors of eithe

69 The clinical, laboratory and histological features of the ch

70 ecords were reviewed, including longitudinal clinical, laboratory and imaging data.

71 al cases were correlated with the results of clinical, laboratory and other imaging studies.

72 Clinical, laboratory and pathologic data were reviewed i

73 We conducted a review of the clinical, laboratory and photographic records to evaluat

74 able for biosensing at the point-of-care, in clinical laboratories, and in research settings.

75 ght contemporary AST challenges faced by the clinical laboratory, and propose some solutions.

76 ewed included demographics, anthropometrics, clinical laboratory, and respiratory physiology.

77 After multivariable adjustment for clinical, laboratory, and angiographic variables, BNP re

78 lasma MBG levels and performed comprehensive clinical, laboratory, and echocardiographic assessment i

79 Safety and efficacy were assessed by clinical, laboratory, and echocardiographic assessments

80 Clinical, laboratory, and epidemiologic evidence suggest

81 ic analysis were used for diagnosis, and the clinical, laboratory, and epidemiological parameters of

82 ent-free diagnostic tests is crucial to many clinical, laboratory, and field applications, including

83 Predictors included longitudinal clinical, laboratory, and histologic data.

84 Clinical, laboratory, and histological reports were anal

85 grade and pattern of iron deposition and the clinical, laboratory, and histological variables was exa

86 Clinical, laboratory, and histopathologic data for both

87 algorithm (1:1) to account for pretreatment clinical, laboratory, and imaging covariates.

88 Recently developed algorithms including clinical, laboratory, and imaging criteria demonstrated

89 sis: Recently developed algorithms including clinical, laboratory, and imaging criteria demonstrated

90 Retrospective review of the clinical, laboratory, and imaging data of 77 patients.

91 We reviewed clinical, laboratory, and imaging data on 78 patients wi

92 Multivariable analyses using clinical, laboratory, and imaging data were also perform

93 We analyzed correlations between clinical, laboratory, and imaging data with number of ho

94 spectively), whereas some characteristic TTD clinical, laboratory, and imaging findings were absent.

95 Several clinical, laboratory, and imaging tests are now being in

96 Distinct clinical, laboratory, and imaging variables are associat

97 have systematically examined the accuracy of clinical, laboratory, and imaging variables in detecting

98 nd without POAF were compared on a number of clinical, laboratory, and instrumental data.

99 Clinical, laboratory, and microbiological data were coll

100 Clinical, laboratory, and outcome data were compared for

101 predictors of clinical outcome from among 30 clinical, laboratory, and pharmacokinetic variables.

102 These disorders are marked by clinical, laboratory, and physiologic heterogeneity.

103 Clinical, laboratory, and physiological variables and da

104 iscovery research can be performed utilizing clinical, laboratory, and procedure data obtained during

105 Detailed recommendations on the initial clinical, laboratory, and radiographic assessment of ECD

106 Clinical, laboratory, and radiology data of overall 43 p

107 A combination of clinical, laboratory, and sonography findings can be pot

108 Clinical, laboratory, and treatment variables associated

109 t for differences in baseline and changes in clinical, laboratory, and ultrasonic characteristics, HI

110 15 years were offered surveillance (periodic clinical, laboratory, and ultrasound evaluations).

111 All participants were submitted to clinical, laboratory, and ultrasound examinations.

112 th mumps were investigated, and demographic, clinical, laboratory, and vaccination data were evaluate

113 We reviewed available clinical, laboratory, and virologic data from all patien

114 Clinical laboratories are constantly facing challenges t

115 Moreover, the cutoffs used in different clinical laboratories are heterogeneous.

116 Clinical laboratories are increasingly reporting estimat

117 Clinical laboratories are now using WGS for pathogen ide

118 nificantly improved analytical efficiency in clinical laboratories as well as for point-of-care tobac

119 round-times, supporting their utility in the clinical laboratory as routine diagnostic platforms.

120 y Improvement Amendments-approved commercial clinical laboratories, as reported to the Prospective Re

121 CLA Ronald Reagan Medical Center traditional clinical laboratory assay (correlation coefficient = 0.9

122 easurements were compared to the traditional clinical laboratory assay.

123 ditionally, diagnosis has relied on multiple clinical laboratory assays to assign VWD phenotype.

124 rmed (skin biopsy, subcutaneous provocation, clinical/laboratory assessment for thrombosis, bleeding,

125 Clinical laboratory assessments generally remained uncha

126 of ivacaftor as assessed by adverse events, clinical laboratory assessments, electrocardiograms, vit

127 plicability of the technique to the field of clinical laboratory automation.

128 and reproducibility comparable to that of a clinical laboratory-based third-generation TSH immunoass

129 ve supplanted microbiological assays in many clinical laboratories because of their ease of use.

130 d implementation of sequencing assays in the clinical laboratory, but it has limited throughput, and

131 Use of the EAPCRI recommendations by clinical laboratories can further enhance PCR performanc

132 This study determined the clinical laboratory capabilities of these ETCs.

133 ETCs were electronically surveyed on clinical laboratory characteristics.

134 l advance toward the development of reliable clinical laboratory- compatible multicolor RNA FISH meth

135 unt of species diversity not seen in routine clinical laboratory cultures.

136 When mecA is detected by PCR in the clinical laboratory, current guidelines recommend that t

137 Clinical laboratories currently utilize an array of diff

138 More generally we illustrate how clinical laboratory data can be used to develop and to t

139 Clinical laboratory data shows that most results are wit

140 r of inputs that are readily obtainable from clinical laboratory data.

141 apacity of RNA-Seq was compared to available clinical laboratory data.

142 enced the Swedish Dementia Registry with the clinical laboratory database at the Sahlgrenska Universi

143 has all the necessary features suitable for clinical laboratories demanding high-throughput sample p

144 The identification of VISA in the clinical laboratory depends on standard susceptibility t

145 e Aptima ZIKV assay an attractive choice for clinical laboratories detecting ZIKV RNA from serum and

146 The clinical laboratory diagnosis of cutaneous anthrax is ge

147 inical implications of Bcc identification, a clinical laboratory differentiation of species within th

148 le electronic survey, health administrative, clinical, laboratory, drug, and electronic medical recor

149 al samples (n = 531) submitted to a regional clinical laboratory during a 6-month period were tested

150 7 patients with HFpEF and performed detailed clinical, laboratory, ECG, and echocardiographic phenoty

151 rt Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmo

152 ient care by integrating data extracted from clinical, laboratory, echocardiographic, and genetic ass

153 We compared clinical, laboratory, echocardiographic, and uteroplacen

154 We evaluated a series of demographic, clinical, laboratory, electrocardiographic, and echocard

155 sms to supplement existing techniques in the clinical laboratory, especially in single bacterial colo

156 , fever (temperature >/=38.0 degrees C), and clinical laboratory evaluations for infection (urine cul

157 says rapidly evolving into routine practice, clinical laboratories face several challenges, including

158 A positive tuberculin skin test alone among clinical laboratory findings was significantly associate

159 antial changes from baseline in vital signs, clinical laboratory findings, or electrocardiography fin

160 Because of the inconclusive results of both clinical-laboratory findings and ultrasonography, CT ima

161 for inpatient and outpatient procedures, to clinical laboratories for diagnostic tests, and to pharm

162 MS)-based identification is being adopted by clinical laboratories for routine identification of micr

163 specimens sent to the Johns Hopkins Hospital clinical laboratory for viral quantitative real-time pol

164 Twenty-two (50%) of these ETC clinical laboratories had biosafety level 3 (BSL-3) cont

165 As a result, many high-volume clinical laboratories have begun to offer a reverse syph

166 or the detection of carbapenemases; however, clinical laboratories have struggled for years with accu

167 h reduced ejection fraction who had complete clinical, laboratory, health-related quality of life, im

168 n sequencing technology is available to many clinical laboratories; however, it is not yet widely use

169 uld be less expensive and time-consuming for clinical laboratories; however, this approach would be b

170 nson's disease will rely on a combination of clinical, laboratory, imaging, and genetic data.

171 e functional class in perspective with other clinical, laboratory, imaging, and hemodynamic parameter

172 iplinary process that incorporates available clinical, laboratory, imaging, and histological features

173 usions and Relevance: Combined findings from clinical, laboratory, imaging, and pathological examinat

174 y 2016 if laboratories choose not to perform Clinical Laboratory Improvement Act (CLIA) default QC.

175 DNA/RNA with tumour/normal comparisons in a Clinical Laboratory Improvement Amendments (CLIA) compli

176 selected concentrations were all within the Clinical Laboratory Improvement Amendments (CLIA) criter

177 levant across multiple tumor lineages in the Clinical Laboratory Improvement Amendments (CLIA) enviro

178 of N. gonorrhoeae were tested following the Clinical Laboratory Improvement Amendments (CLIA)-approv

179 ated in a multicenter prospective trial in a Clinical Laboratory Improvement Amendments (CLIA)-waived

180 rgeted next-generation sequencing assay in a Clinical Laboratory Improvement Amendments laboratory.

181 conflicting variant interpretations between Clinical Laboratory Improvement Amendments-approved comm

182 hout the United States and Canada can obtain Clinical Laboratory Improvement Amendments-certified cli

183 lege of American Pathologists-accredited and Clinical Laboratory Improvement Amendments-certified cli

184 levant time frame, which is performed in our Clinical Laboratory Improvement Amendments-certified Col

185 therapy should have their tumor tested in a Clinical Laboratory Improvement Amendments-certified lab

186 hort, using a diagnostic DNA microarray in a Clinical Laboratory Improvement Amendments/International

187 latform for routine use in PHLs according to Clinical Laboratory Improvements Act (CLIA) guidelines f

188 of the gene expression assays were done in a Clinical Laboratory Improvements Amendments certified la

189 Clinical laboratories in areas with resistance levels si

190 rdance was more than twice as frequent among clinical laboratories in ClinVar, a public archive of va

191 Additionally, a survey of 17 clinical laboratories in northern California demonstrate

192 10-2011) consecutive E. coli isolates from 5 clinical laboratories in Seattle, Washington, and Minnea

193 The proposed QC ranges would aid clinical laboratories in testing these compounds followi

194 Many clinical laboratories in the United States are transitio

195 are one of the most common platform used in clinical laboratories, in particular the class based on

196 urrent methods for pathogen detection in the clinical laboratory include biological culture, nucleic

197 spectrometry technology to most research and clinical laboratories, including those in developing cou

198 ensitivity of this medium, we recommend that clinical laboratories incorporate BHI-V3 to screen for v

199 plore the use of whole-genome sequencing for clinical laboratory investigations of MRSA molecular epi

200 Recognition of resistance by the clinical laboratory is complicated by the multiple FQ re

201 icrobial susceptibility testing (AST) by the clinical laboratory is paramount to combating antimicrob

202 n of new DNA sequencing methodologies to the clinical laboratory is under way and is likely to have a

203 for Lyme disease at a single hospital-based clinical laboratory located in an area endemic for Lyme

204 fety assessments included adverse events and clinical laboratory measures, assessed in all treated pa

205 granular lymphocyte populations by standard clinical laboratory methods (flow cytometry, examination

206 Large hospital-based clinical laboratories must be prepared to rapidly invest

207 Animal and Plant Health Inspection Service, clinical laboratories must be proficient at rapidly reco

208 PCR instrumentation, and is well suited for clinical laboratories offering IL28B genotyping.

209 l identification becomes more commonplace in clinical laboratories, one can expect to see changes in

210 risk of progressive liver disease, based on clinical, laboratory, or imaging findings.

211 eiving mechanical ventilation, those without clinical, laboratory, or radiologic evidence of bacteria

212 The clinical, laboratory parameters, etiology of liver cirrh

213 outcomes included adverse events (AEs), and clinical/laboratory parameters.

214 ue to assay incubation periods and a lack of clinical laboratories performing these tests.

215 lignment program with several advantages for clinical laboratories performing virus sequencing compar

216 Clinical laboratories play a key role in reducing this b

217 and Laboratory Standards Institute and Good Clinical Laboratory Practices guidelines for evaluating

218 ratory clinic was screened prospectively for clinical, laboratory, radiologic, and (when appropriate)

219 The clinical, laboratory, radiologic, and pathologic finding

220 s, a repository of socioeconomic/geographic, clinical, laboratory, radiological, and genomic data fro

221 Quantitative immunoassay tests in clinical laboratories require trained technicians, take

222 The majority had worked in Sierra Leone in clinical, laboratory, research, and other roles.

223 nternational Consortium for Harmonization of Clinical Laboratory Results to coordinate harmonization

224 he use of real-time PCR in a quality assured clinical laboratory setting can be sensitive to low-leve

225 ion of Gram-positive aerobic bacteria in the clinical laboratory setting.

226 DDs requiring rapid therapeutic actions in a clinical laboratory setting.

227 Eight large clinical laboratories, seven from the United States and

228 Collaboration among clinical laboratory staff, health professionals, and law

229 r setting breakpoints for voriconazole using Clinical Laboratory Standards Institute (CLSI) and Europ

230 and agreement was assessed based on MICs and Clinical Laboratory Standards Institute (CLSI) interpret

231 The Clinical Laboratory Standards Institute (CLSI) recently

232 nded by the different methods recommended by Clinical Laboratory Standards Institute and Internationa

233 inhibitory concentrations using revised 2011 Clinical Laboratory Standards Institute breakpoints unco

234 Based on POCT12-A3, the Clinical Laboratory Standards Institute standard for hos

235 stitute (formerly the National Committee for Clinical Laboratory Standards).

236 ed in hypertrophic cardiomyopathy than among clinical laboratories, suggesting that optimal genetic t

237 protein amount of substance content between clinical laboratories, suitable reference materials are

238 cated that their hospital would also provide clinical laboratory support for patient care.

239 e profile was in agreement with the original clinical laboratory susceptibility profile, and the toxi

240 We identified clinical, laboratory, systemic, and radiologic features

241 correlation with standard spectrophotometric clinical laboratory techniques was found.

242 r was associated with solvent exposure among clinical laboratory technologists and technicians (HR, 2

243 ease Control and Prevention recommended that clinical laboratories test all stools submitted for the

244 Clinical laboratories test for extended-spectrum beta-la

245 Five clinical laboratories tested 722 positive blood culture

246 es and provide the foundation for developing clinical laboratory testing strategies to guide therapeu

247 renal insufficiency, limited experience with clinical laboratory testing to confirm lack of residual

248 th new-onset overweight or obesity underwent clinical laboratory testing, including oral glucose tole

249 Clinical laboratory tests are now being prescribed and m

250 Clinical laboratory tests of thyroid function (including

251 and neurological examinations, vital signs, clinical laboratory tests, cerebrospinal fluid laborator

252 s and protocols to establish traceability of clinical laboratory tests, have been established and con

253 fety measures included adverse events (AEs), clinical laboratory tests, vital signs, electrocardiogra

254 ng binding to streptavidin, are used in many clinical laboratory tests.

255 ypical changes of Ebola hemorrhagic fever in clinical laboratory tests.

256 R, quality of life, safety, vital signs, and clinical laboratory tests.

257 otes and electrocardiograms, procedures, and clinical laboratory tests.

258 These data may assist clinical laboratories that are considering implementing

259 cytomegalovirus performed at three different clinical laboratories that use the same methodology.

260 Analyses were conducted in a clinical laboratory that performs DNA sequencing.

261 Despite its growing use in clinical laboratories, the accuracy of 3DE has not been

262 culture reference method that is used in the clinical laboratories, this new device performed well in

263 We encourage clinical laboratories to adopt the revised CLSI ciproflo

264 Based on these data, we urge clinical laboratories to be aware of the variable result

265 In 2005, FoodNet conducted a survey of clinical laboratories to describe routine practices used

266 ation tests and mass spectroscopy that allow clinical laboratories to detect and identify organisms f

267 ssays (EIAs) are the primary methods used by clinical laboratories to detect enteric bacterial pathog

268 strate the potential of the MinION device in clinical laboratories to fully characterize the epidemic

269 ntibody detection systems enable high-volume clinical laboratories to perform syphilis screening at a

270 alidation trials, and the limited ability of clinical laboratories to process and analyze complex bio

271 lthough centrifuges are ubiquitously used in clinical laboratories to separate plasma from whole bloo

272 practice by providing a firm foundation for clinical laboratories to set appropriate cutoffs.

273 methodology that will enable hospital-based clinical laboratories to support cefepime MIC-based dosi

274 A validation study was performed in a single clinical laboratory to determine the accuracy of the mCI

275 atistical physics and data from the hospital clinical laboratory to develop a master equation model f

276 es for whole-exome sequencing in a certified clinical laboratory to identify sequence variants underl

277 It is important for the clinical laboratory to interpret the molecular findings

278 e well suited to the increasing research and clinical laboratories undertaking exome sequencing, part

279 fficient assay workflow suitable for routine clinical laboratory use, with the flexibility to be modi

280 Currently, most clinical laboratories utilize rapid immunoassays that ar

281 elated serious adverse events, or changes in clinical laboratory values or vital signs occurred durin

282 Adverse events, clinical laboratory values, and electrocardiograms were

283 Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 33

284 Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-erenum

285 We prospectively characterized the clinical, laboratory, virologic and immunologic features

286 ay demonstrated correlation with traditional clinical laboratory VWF assays.

287 S panel to improve the diagnostic yield in a clinical laboratory was shown.

288 Laboratory Improvement Amendments-certified clinical laboratory, we quantified digital pathology fea

289 Patient GAS isolates from clinical laboratories were also obtained.

290 as until now required the use of centralized clinical laboratories which require specimen transport,

291 nd associated technologies are evolving, and clinical laboratories will need to invest significantly

292 With this approach, the clinical laboratory will be asked to select what AST met

293 This subtyping IFA provides clinical laboratories with a cost-effective diagnostic t

294 To provide clinical laboratories with a definitive immunofluorescen

295 The enhanced mPLUS capability provides clinical laboratories with increased efficiencies to mee

296 d tumor samples underwent WES in a certified clinical laboratory with genetic results categorized on

297 of human bacterial pathogens in real time in clinical laboratories, with little specialist training r

298 on of clinically important microorganisms in clinical laboratories without any preanalysis preparativ

299 aerobic actinomycetes isolates under routine clinical laboratory working conditions over a 6-month pe

300 As clinical laboratories worldwide use calibrators traceabl